Hemodialysis Vascular Grafts Market: as Xeltis moves aXess from first-in-human data through FDA Breakthrough Device Designation to European commercial launch within roughly three years, bioengineered graft technology is transitioning from a research curiosity into a genuine ePTFE alternative, so the two-decade material stalemate the category's restraints describe may be closer to ending than the incumbents' current 53% ePTFE share suggests.

The global hemodialysis vascular grafts market size was USD 231 Million in 2025 and is expected to register a revenue CAGR of 5.1% during the forecast period.The hemodialysis vascular grafts market encompasses synthetic and biological graft implants surgically placed to connect an artery to a vein, creating an artificial arteriovenous circuit for hemodialysis needle access in patients not candidates for native arteriovenous fistula creation due to inadequate vessel anatomy, prior vascular surgery, advanced age, or urgent dialysis access requirement.Market revenue growth is supported by the growing global ESRD patient population, with the WHO reporting approximately 850 million people worldwide affected by kidney diseases of various causes, and the sustained proportion of patients with vessel anatomy unsuitable for native AVF creation.Terumo Corporation's Flixene Vascular Graft provides a tapered PTFE configuration that enhances haemodynamics and minimises intimal hyperplasia at the venous anastomosis through its tapered lumen design that reduces turbulent blood flow.BD received FDA 510(k) clearance in April 2023 for its Aspirex mechanical suction thrombectomy system for clot removal from both arteriovenous grafts and native arteriovenous fistulas, adding an interventional patency-maintenance option adjacent to the graft care pathway.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a bioengineered graft platform widens its addressable market every time it clears a new regulatory milestone on the same underlying restorative technology, converting a research programme into a genuinely reimbursable clinical alternative without requiring an entirely new device concept.Once a bioengineered graft demonstrates first-in-human safety and patency data, each subsequent regulatory milestone, breakthrough designation, pivotal trial initiation, CE mark, and commercial launch, converts a larger share of the addressable patient population from ePTFE default to a genuine material choice, so revenue potential compounds as the technology's regulatory maturity accumulates rather than requiring a wholly new clinical adoption cycle each time.As a result, demand and revenue share are beginning to shift toward technologies with the most advanced bioengineered regulatory pathway, that hold the deepest multi-year patency evidence versus ePTFE, and the forecast increasingly accounts for a genuine material transition risk rather than treating ePTFE's incumbent position as structurally permanent.For instance, on July 7, 2026, Xeltis announced the official start of European commercialisation of its aXess bioengineered vascular access graft, marked by the first commercial patient treatment in Germany, following positive 12-month European pivotal data demonstrating secondary patency comparable to matured arteriovenous fistulas alongside lower reintervention rates and high infection resistance compared with historical arteriovenous graft benchmarks.These are some of the key factors driving revenue growth of the market.

Because native arteriovenous fistula provides superior long-term patency, lower infection risk, lower hospitalisation rate, and lower intervention burden compared to synthetic arteriovenous grafts, medical society guidelines and insurer incentive structures prioritise fistula creation over graft placement and actively restrict graft use to patients with documented inadequate vessel anatomy.

Cumulative graft failure and intervention burden is a second constraint, as primary and secondary graft failure rates driven by thrombosis and neointimal hyperplasia at the venous anastomosis require intervention with balloon angioplasty, mechanical thrombectomy, or graft replacement procedures that add cumulative cost compared to functional AVF.

Emerging alternative technology competition is a third constraint, with the percutaneous HeRO Graft for patients with central venous stenosis and next-generation bioengineered grafts signalling evolving alternatives that may challenge ePTFE's dominant material position over the forecast period.

These factors substantially limit hemodialysis vascular grafts market growth over the forecast period.

The clearest driver of demand is the interventional ecosystem that has grown up around sustaining synthetic graft patency once thrombosis occurs. A synthetic graft only remains a viable long-term access modality if clinicians have effective tools to reverse thrombotic occlusion without replacing the entire graft, and BD's Aspirex system does exactly that through a three-pronged mechanism of mechanical transportation, continuous clot maceration, and enhanced clot aspiration. Thrombosis of the synthetic arteriovenous graft lumen occurs at a rate of 0.5 to 1.5 thrombotic events per patient-year at functional synthetic grafts, substantially higher than the thrombosis rate of mature native AVFs. Terumo Corporation's Flixene Vascular Graft provides a tapered PTFE configuration that reduces turbulent haemodynamics at the venous anastomosis where neointimal hyperplasia preferentially develops, positioning it as a differentiated ePTFE graft competing with W.L. Gore IMPRA's established market position through anatomical design evidence. The effect on the market is that the availability of mechanical thrombectomy tools sustains graft primary-assisted and secondary patency through repeated intervention, keeping graft placement as a functional access modality and a recurring replacement demand category when intervention eventually fails. These are some of the key factors driving revenue growth of the market.

The second driver is the accelerating regulatory maturation of bioengineered vascular graft technology. A bioengineered graft only earns commercial adoption once it has demonstrated patency performance that genuinely rivals native fistula outcomes, not just improves modestly on ePTFE, and Xeltis's 12-month European pivotal data, showing secondary patency comparable to matured arteriovenous fistulas, cleared exactly that bar. In July 2025, Xeltis received FDA Breakthrough Device Designation for aXess and treated its first patient in the US pivotal trial, building on a first-in-human trial that had already treated over 100 patients across Xeltis's broader endogenous tissue restoration platform. On July 7, 2026, Xeltis announced the official start of European commercialisation of aXess, marked by the first commercial patient treatment at Artemed Klinikum Munich South, Germany, introducing what the company describes as a new category of vascular access that transforms into the patient's own living vessel over time. The effect on the market is that the two-decade absence of a clinically meaningful synthetic graft patency improvement that the market's restraints have long described may be ending, with bioengineered technology now positioned to capture patients with prior synthetic graft failure first and potentially a broader population over time. These are some of the key factors driving revenue growth of the market.

“Xeltis's aXess bioengineered graft delivered secondary patency comparable to matured arteriovenous fistulas in 12-month European pivotal data, the first synthetic-alternative technology in two decades to approach native fistula performance.”

However, the hemodialysis vascular grafts market faces severe adoption constraints from AVF guideline preference and insurer incentive structures, cumulative graft failure and intervention burden, and emerging alternative technology competition.

Because AVF guideline preference and insurer incentive structures actively restrict graft use to anatomically unsuitable patients, this creates a structurally capped addressable population for synthetic graft placement regardless of material innovation.

Cumulative graft failure and intervention burden is a second constraint, as primary and secondary graft failure from thrombosis and neointimal hyperplasia at venous anastomosis sites requires repeated balloon angioplasty, thrombectomy, or replacement procedures that add cumulative cost versus functional AVF.

Emerging alternative technology competition is a third constraint, since competition from the HeRO Graft for central venous stenosis patients and from bioengineered graft clinical development signals evolving alternatives to ePTFE's dominant position that could fragment the synthetic graft market further before consolidating around a new standard.

These factors substantially limit hemodialysis vascular grafts market growth over the forecast period.

Based on material, the global hemodialysis vascular grafts market is segmented into ePTFE, polyurethane, and biological tissue grafts. ePTFE accounts for the largest revenue share at approximately 53% of 2025 market revenue. Expanded polytetrafluoroethylene grafts, including the W.L. Gore GORE IMPRA ePTFE graft family, have been the clinical standard for synthetic hemodialysis vascular access graft placement since the 1980s, with established clinical evidence establishing safety and patency benchmarks. Polyurethane grafts, including BD's VENATECH polyurethane graft, offer greater flexibility and kink resistance than traditional ePTFE options and feature infection-resistant coatings with reduced needle-hole bleeding, representing a material alternative for difficult patient anatomies.

Based on end-use, the global hemodialysis vascular grafts market is segmented into dialysis centres, hospitals and vascular surgery programmes, and ambulatory surgical centres. Dialysis centres account for the largest revenue share at approximately 46% of 2025 market revenue. The hospitals and vascular surgery segment accounts for approximately 36% and includes the primary surgical graft placement procedure performed by vascular surgeons in hospital operating room settings. Asia Pacific is expected to register the fastest CAGR in the market over the forecast period, driven by China's growing ESRD patient population with rising prevalence of diabetic nephropathy and hypertensive kidney disease.

Based on regional analysis, North America accounted for approximately 39% of global hemodialysis vascular grafts revenue in 2025, with the United States accounting for approximately USD 93.7 Million of 2024 global market revenue. North America benefits from established CMS ESRD programme reimbursement for arteriovenous graft placement and revision procedures, and the commercial presence of W.L. Gore & Associates and BD as the two primary synthetic graft manufacturers with direct US hospital and vascular surgery account relationships. BD's Aspirex mechanical thrombectomy clearance supports graft patency maintenance at the US interventional nephrology programme level.

The market in Asia Pacific is expected to register the fastest revenue growth rate in the global hemodialysis vascular grafts market over the forecast period.

Japan, China, South Korea, and Australia represent the four largest national hemodialysis vascular graft markets, with the region registering approximately 6.87% CAGR over the forecast period. China's forecast USD 105.7 Million market by 2030 at 7.7% CAGR represents the fastest-growing single national market within Asia Pacific, driven by rapid ESRD incidence growth from diabetic nephropathy and hypertensive kidney disease in a population where chronic kidney disease affects approximately 10% of the general population. Japan's established vascular access programme density and sophisticated interventional nephrology capability create a mature synthetic graft maintenance market sustained by Japan's large in-centre hemodialysis patient population.

The market in Europe is expected to register a steady revenue growth rate in the global hemodialysis vascular grafts market over the forecast period.

Germany, France, the United Kingdom, and Italy represent the four largest national hemodialysis vascular graft markets in Europe. The European Vascular Access Society congress and European Renal Association guidelines provide the clinical framework for arteriovenous graft use, with Xeltis's Netherlands-based aXess development and July 2026 first commercial implant in Germany reflecting Europe's role as the leading market for next-generation vascular graft technology.

Latin America and Middle East and Africa markets are expected to register moderate revenue growth rates in the global hemodialysis vascular grafts market over the forecast period.

Brazil and Mexico represent the two largest national hemodialysis vascular graft markets in Latin America, with growing ESRD patient populations and expanding vascular surgery access at private hospital networks in São Paulo. Saudi Arabia and the UAE represent the primary GCC markets, with the Saudi Vision 2030 healthcare infrastructure expansion including nephrology and dialysis programme development requiring vascular access surgical capability and synthetic graft procurement.